EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics

Georgios Nikolakis iD, Erkan Alpsoy iD, Monika Arenbergerova, Falk G Bechara, Farida Benhadou, Joana Cabete, Raffaele Dante Caposiena Caro iD, Giovanni Damiani, Maia Delage Toriel, Veronique Del Marmol, Valentina Dini iD, Evangelos J Giamarellos-Bourboulis iD und 30 weitere

Journal of the European Academy of Dermatology and Venereology · 2026-04 · 40 (4) · 658-669

DOI: 10.1111/jdv.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 13.11.2025. Verfasst von Georgios Nikolakis und 41 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Facu…. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Biological Products, Anti-Bacterial Agents, Practice Patterns, Physicians'. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized primarily by dysregulated innate immunity and abnormal keratinocyte differentiation. Over the past two decades, the treatment paradigm has evolved from antibiotics to targeted biologics, such as anti‐TNF‐α and anti‐IL‐17A/A‐F inhibitors. However, antibiotic therapy remains a prerequisite for biologic initiation despite a lack of comparative studies evaluating their efficacy.

Objectives

This study aimed to assess current prescription patterns for systemic HS therapies among European HS specialists, evaluate unmet needs in antibiotic and biologic use and explore expert opinions on criteria for biologic upgrade as a first‐line therapy.

Methods

A structured questionnaire was distributed to 55 HS specialists, the majority of whom were members of the European Hidradenitis Suppurativa Foundation (EHSF), comprising HS experts and future opinion leaders. Responses underwent statistical analysis to assess trends in antibiotic versus biologic prescription, treatment efficacy and potential improvements in therapeutic decision‐making.

Results

A total of 43 participants (76.6% of invited experts, 80% of invited opinion leaders) responded. While 95% adhered to licensing regulations mandating 10–12 weeks of antibiotics before biologics, 81% acknowledged prescribing antibiotics despite anticipating inadequate responses. More than half reported patient‐reported flares during antibiotic treatment. The majority (77%) supported earlier biologic initiation in cases of persistent flares, and 79% favoured short‐term biologic therapy over antibiotics for early‐stage HS. Participants identified specific phenotypic attributes such as rapidly progressing disease, extensive involvement and comorbidities as factors warranting earlier biologic intervention.

Conclusions

Current treatment practice may delay optimal intervention, potentially leading to missed therapeutic windows. A significant proportion of respondents expressed a preference for earlier biologic intervention, especially in cases of severe disease or frequent flares. The findings underscore the need for a consensus statement defining upgrade criteria for biologics as a first‐line therapy, potentially improving patient outcomes and reducing healthcare burdens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaBiological ProductsAnti-Bacterial AgentsPractice Patterns, Physicians'HumansSurveys and QuestionnairesMaleEuropeFemale

Stichwörter der Autor:innen

adalimumabbimekizumabbiologicshidradenitis suppurativasecukinumabupgrade criteria

Substanzen

Biological ProductsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
  • European Hidradenitis Suppurativa Foundation e.V., Dessau, Germany.
  • Department of Dermatology and Venereology, Akdeniz University, Antalya, Türkiye.
  • Department of Dermatovenerology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • International Centre for Hidradenitis Suppurativa/Acne Inversa (ICH), Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany.
  • Department of Dermatology, Hôpitaux Universitaires de Bruxelles (HUB), Université libre de Bruxelles, Brussels, Belgium.

ORCID-Profile: Georgios Nikolakis, Erkan Alpsoy, Raffaele Dante Caposiena Caro, Valentina Dini, Evangelos J Giamarellos-Bourboulis, Philippe Guillem, Ariela Hafner, Gregor B E Jemec, Niamh Kearney, Natalia Kirsten, Flavia Manzo Margiotta, Angelo V Marzano, Alejandro Molina Leyva, Francesca Prignano, Tadas Raudonis, Kelsey Van Straalen, Christos C Zouboulis

Zitieren

APA

Nikolakis, G., Alpsoy, E., Arenbergerova, M., Bechara, F. G., Benhadou, F., Cabete, J., Caro, R. D. C., Damiani, G., Delage Toriel, M., Del Marmol, V., Dini, V., Giamarellos-Bourboulis, E. J., Glasenhardt, K., Guillem, P., Hafner, A., Hristakieva, E., Ingram, J. R., Jarienè, V., Jemec, G. B. E., …, & Zouboulis, C. C. (2026). Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics. Journal of the European Academy of Dermatology and Venereology, 40(4), 658-669. https://doi.org/10.1111/jdv.70118

Vancouver

Nikolakis G, Alpsoy E, Arenbergerova M, Bechara FG, Benhadou F, Cabete J, et al. Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics. Journal of the European Academy of Dermatology and Venereology. 2026;40(4):658-669. doi:10.1111/jdv.70118

BibTeX
@article{Nikolakis2026,
  author = {Nikolakis, Georgios and Alpsoy, Erkan and Arenbergerova, Monika and Bechara, Falk G and Benhadou, Farida and Cabete, Joana and Caro, Raffaele Dante Caposiena and Damiani, Giovanni and Delage Toriel, Maia and Del Marmol, Veronique and Dini, Valentina and Giamarellos-Bourboulis, Evangelos J and Glasenhardt, Katalin and Guillem, Philippe and Hafner, Ariela and Hristakieva, Evgeniya and Ingram, John R and Jarienè, Vaiva and Jemec, Gregor B E and Kearney, Niamh and Kirby, Brian and Kirsten, Natalia and Krajewski, Piotr K and Kucinskiene, Vesta and Liakou, Aikaterini I and Manzo Margiotta, Flavia and Marzano, Angelo V and Martorell, Antonio and Matusiak, Lukasz and Mintoff, Dillon and Molina Leyva, Alejandro and Prignano, Francesca and Raudonis, Tadas and Ring, Hans Christian and Romanelli, Marco and Şahin, Samed and Saunte, Ditte M L and Thorlacius, Linnea and Tzellos, Thrasyvoulos and Van Der Zee, Hessel H and Van Straalen, Kelsey and Zouboulis, Christos C},
  title = {Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {4},
  pages = {658--669},
  doi = {10.1111/jdv.70118}
}
Kostenlos starten →